Clinical Trial Update: Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating pirtobrutinib in combination with rituximab, gemcitabine, oxaliplatin, with or without polatuzumab vedotin in covalent BTK inhibitor-pr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• OXALIPLATIN (Oxaliplatin)
• Pirtobrutinib (pirtobrutinib)
• Polivy (polatuzumab vedotin)
• Rituxan (rituximab)

Snippet

Sponsor: Ruijin Hospital | Conditions: Relapsed and Refractory DLBCL | Phase 2 | Status: NOT_YET_RECRUITING